Back to search results

Tocilizumab and Atezolizumab for Advanced Non-Small Cell Lung Cancer

This research study is testing the safety and effectiveness of two drugs, tocilizumab and atezolizumab, for adults with advanced non-small cell lung cancer. You might be able to join if your cancer has progressed after previous treatment that included a checkpoint inhibitor (a type of immunotherapy). The study is looking to see how many participants respond to the treatment, measured at 12 weeks after the first dose. The study aims to enroll 28 participants, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It is planned to enroll 28 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, overall response rate, is measured at 12 weeks from the first dose of treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04691817

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Recruiting
PHASE1Ages 18+InterventionalTreatment
Abramson Cancer Center at Penn Medicine
~28 participants
Updated 2026-01-07 on ClinicalTrials.gov
What's tested:AtezolizumabTocilizumab

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Overall response rate (ORR)
Measured over From first dose of protocol treatment until radiologic disease assessment at 12 weeks.

Conditions

Lung Cancer, Nonsmall Cell

Explore related trials

Lung Non-Small Cell Carcinoma

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • Melina Marmarelis, MD, MSCE · PRINCIPAL_INVESTIGATOR · Abramson Cancer Center at Penn Medicine

Who to contact

Melissa Volpe, BA
[email protected]
215-220-9703
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older
Prior exposure to at least 1 line of therapy
Exposure to a including checkpoint inhibitor in line of therapy immediately prior to enrollment on trial
ECOG PS 0-2

Exclusion

Presence of a driver mutation that is susceptible to targeted therapy
No greater than CTCAE v5 grade 3 toxicity attributed to prior immunotherapy
Other active invasive malignancy requiring ongoing therapy
Evidence of progressing or untreated brain metastases
Evidence or history of leptomeningeal disease
Uncontrolled tumor related pain
History of an autoimmune disease or IPF

What this trial measures

  • Overall response rate (ORR)From first dose of protocol treatment until radiologic disease assessment at 12 weeks.

    Assess the proportion of patients with a radiologic response by RECIST 1.1 at 12 weeks.